Targeting the Oncogenic Tyrosine Kinase NPM-ALK in Lymphoma: The Role of Murine Models in Defining Pathogenesis and Treatment Options

Title: Targeting the Oncogenic Tyrosine Kinase NPM-ALK in Lymphoma: The Role of Murine Models in Defining Pathogenesis and Treatment Options

Volume: 7 Issue: 10

Author(s): Cornelius Miething, Christian Peschel and Justus Duyster

Affiliation:

Keywords: oncoprotein, NPM ALK-protein expression, malignancy, CD 30, xenograft model

Abstract: Oncogenic tyrosine kinases play a ever growing role in the pathogenesis of human malignancies. In human non-hodgkin lymphomas, the NPM-ALK oncogene arising from the t(2;5) chromosomal translocation represents the most important oncogenic tyrosine kinase identified so far. The ALK-kinase is constitutively activated by NPM-induced dimerization and signals through a multitude of growth promoting and antiapoptotic pathways. Murine models have made a significant impact on the elucidation of the molecular pathogenesis and new treatment options of malignant diseases. Here, the latest developments in the analysis of NPM-ALK induced lymphomagenesis by murine models is reviewed.

Cite this article as:

Miething Cornelius, Peschel Christian and Duyster Justus, Targeting the Oncogenic Tyrosine Kinase NPM-ALK in Lymphoma: The Role of Murine Models in Defining Pathogenesis and Treatment Options, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559229